Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors
DC Metz, RT Jensen - Gastroenterology, 2008 - Elsevier
Pancreatic endocrine tumors (PETs) have long fascinated clinicians and investigators
despite their relative rarity. Their clinical presentation varies depending on whether the …
despite their relative rarity. Their clinical presentation varies depending on whether the …
Current status of gastrointestinal carcinoids
IM Modlin, M Kidd, I Latich, MN Zikusoka, MD Shapiro - Gastroenterology, 2005 - Elsevier
Gastrointestinal (GI) carcinoids are ill-understood, enigmatic malignancies, which, although
slow growing compared with adenocarcinomas, can behave aggressively. Carcinoids are …
slow growing compared with adenocarcinomas, can behave aggressively. Carcinoids are …
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
JJ Zaknun, L Bodei, J Mueller-Brand, ME Pavel… - European journal of …, 2013 - Springer
Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy
involving the systemic administration of a radiolabelled peptide designed to target with high …
involving the systemic administration of a radiolabelled peptide designed to target with high …
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
L Bodei, M Kidd, G Paganelli, CM Grana… - European journal of …, 2015 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) with 90 Y and 177 Lu provides
objective responses in neuroendocrine tumours, and is well tolerated with moderate toxicity …
objective responses in neuroendocrine tumours, and is well tolerated with moderate toxicity …
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and …
U Garske-Román, M Sandström, K Fröss Baron… - European journal of …, 2018 - Springer
Purpose Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
Tumor-induced osteomalacia
WH Chong, AA Molinolo, CC Chen… - Endocrine-related …, 2011 - erc.bioscientifica.com
Somatostatin receptor imaging (SRI) with [111 In-DTPA 0] octreotide has proven its role in
the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs) …
the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs) …
ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms
G Delle Fave, DJ Kwekkeboom, E Van Cutsem… - …, 2012 - karger.com
Gianfranco Delle Fave a Dik J. Kwekkeboom b Erik Van Cutsem c Guido Rindi d Beata Kos-
Kudla e Ulrich Knigge f Hironobu Sasano g Paola Tomassetti h Ramon Salazar i Philippe …
Kudla e Ulrich Knigge f Hironobu Sasano g Paola Tomassetti h Ramon Salazar i Philippe …
[PDF][PDF] Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
DJ Kwekkeboom, BL Kam, M Van Essen… - Endocrine-related …, 2010 - researchgate.net
Somatostatin receptor imaging (SRI) with [111In-DTPA0] octreotide has proven its role in the
diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). Newer …
diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). Newer …
Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE
E Ilan, M Sandström, C Wassberg… - Journal of nuclear …, 2015 - Soc Nuclear Med
Peptide receptor radionuclide therapy (PRRT) is a promising treatment for patients with
neuroendocrine tumors, giving rise to improved survival. Dosimetric calculations in relation …
neuroendocrine tumors, giving rise to improved survival. Dosimetric calculations in relation …
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
L Bodei, M Cremonesi, M Ferrari, M Pacifici… - European journal of …, 2008 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with 90
Y-DOTATOC and 177 Lu-DOTATATE is promising. The kidney is the critical organ and …
Y-DOTATOC and 177 Lu-DOTATATE is promising. The kidney is the critical organ and …